

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.. Amended 01/01/11

<b>Name of Entity:</b>	Alterity Therapeutics Limited (ASX:ATH)
<b>ABN:</b>	37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director:</b>	Mr. Geoffrey Kempler
<b>Date of Last Notice:</b>	21 September 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Director related entity														
Date of change	14 December 2022														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>30,000</td><td>19,000,000</td></tr><tr><td>Indirect</td><td>17,981,000</td><td>-</td></tr><tr><td>Total</td><td>18,011,000</td><td>19,000,000</td></tr></table>				Shares	Options	Direct	30,000	19,000,000	Indirect	17,981,000	-	Total	18,011,000	19,000,000
	Shares	Options													
Direct	30,000	19,000,000													
Indirect	17,981,000	-													
Total	18,011,000	19,000,000													
Class	Unlisted Options														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>5,000,000</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>5,000,000</td></tr></table>				Shares	Options	Direct	-	5,000,000	Indirect	-	-	Total	-	5,000,000
	Shares	Options													
Direct	-	5,000,000													
Indirect	-	-													
Total	-	5,000,000													
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	n/a														

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	30,000	14,000,000
	<b>Indirect</b>	17,981,000	-
	<b>Total</b>	<b>18,011,000</b>	<b>14,000,000</b>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of incentive options under ESOP		

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder</b> (if issued securities)	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

## Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A



The CFO Solution

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001. Amended 01/01/11

<b>Name of Entity:</b>	Alterity Therapeutics Limited (ASX:ATH)
<b>ABN:</b>	37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director:</b>	Mr. Peter Marks
<b>Date of Last Notice:</b>	21 September 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct		
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-		
Date of change	14 December 2022		
No. of securities held prior to change		Shares	Options
	Direct	-	8,250,000
	Indirect	43,111	-
	Total	43,111	8,250,000
Class	Unlisted Options		
Number acquired		Shares	Options
	Direct	-	-
	Indirect	-	-
	Total	-	-
Number disposed		Shares	Options
	Direct	-	1,250,000
	Indirect	-	-
	Total	-	1,250,000
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	n/a		

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	-	7,000,000
	<b>Indirect</b>	43,111	-
	<b>Total</b>	<b>43,111</b>	<b>7,000,000</b>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of incentive options under ESOP		

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder</b> (if issued securities)	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

## Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A



The CFO Solution

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.. Amended 01/01/11

<b>Name of Entity:</b>	Alterity Therapeutics Limited (ASX:ATH)
<b>ABN:</b>	37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director:</b>	Mr. Brian Meltzer
<b>Date of Last Notice:</b>	21 September 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct														
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-														
Date of change	14 December 2022														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>8,250,000</td></tr><tr><td>Indirect</td><td>326,666</td><td>-</td></tr><tr><td>Total</td><td>326,666</td><td>8,250,000</td></tr></table>				Shares	Options	Direct	-	8,250,000	Indirect	326,666	-	Total	326,666	8,250,000
	Shares	Options													
Direct	-	8,250,000													
Indirect	326,666	-													
Total	326,666	8,250,000													
Class	Unlisted Options														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>1,250,000</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>1,250,000</td></tr></table>				Shares	Options	Direct	-	1,250,000	Indirect	-	-	Total	-	1,250,000
	Shares	Options													
Direct	-	1,250,000													
Indirect	-	-													
Total	-	1,250,000													

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	n/a		
<b>No. of securities held after change</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	-	7,000,000
	<b>Indirect</b>	326,666	-
	<b>Total</b>	<b>326,666</b>	<b>7,000,000</b>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of incentive options under ESOP		

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder</b> (if issued securities)	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

## Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A



The CFO Solution

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001. Amended 01/01/11

<b>Name of Entity:</b>	Alterity Therapeutics Limited (ASX:ATH)
<b>ABM:</b>	37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director:</b>	Mr. Lawrence Gozlan
<b>Date of Last Notice:</b>	21 September 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct		
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-		
<b>Date of change</b>	14 December 2022		
<b>No. of securities held prior to change</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	-	8,250,000
	<b>Indirect</b>	-	-
	<b>Total</b>	-	8,250,000
<b>Class</b>	Unlisted Options		
<b>Number acquired</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	-	-
	<b>Indirect</b>	-	-
	<b>Total</b>	-	-
<b>Number disposed</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	-	1,250,000
	<b>Indirect</b>	-	-
	<b>Total</b>	-	1,250,000

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	n/a		
<b>No. of securities held after change</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	-	7,000,000
	<b>Indirect</b>	-	-
	<b>Total</b>	-	<b>7,000,000</b>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of incentive options under ESOP		

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder</b> (if issued securities)	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

## Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A



The CFO Solution

+ See chapter 19 for defined terms.